Combination of paclitaxel with rosiglitazone induces synergistic cytotoxic effects in ovarian cancer cells.

ABSTRACT: Ovarian cancer is known to be a challenging disease to detect at an early stage and is a major cause of death among women. The current treatment for ovarian cancer typically involves a combination of surgery and the use of drugs such as platinum-based cytotoxic agents, anti-angiogenic drugs, etc. However, current treatment methods are not always effective in preventing the recurrence of ovarian cancer. As a result, the treatments administered after a relapse need to be more aggressive, leading to increased toxicity and drug resistance. To address this issue, researchers are exploring the potential of combining existing anticancer agents with novel or repurposed drugs to reduce the side effects and improve the effectiveness of treatment. In this study, we have investigated the use of rosigl

SUBMITTER: Patel B 

PROVIDER: S-EPMC11680578 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature